应用三维次谐波辅助压力估计与超声造影剂成像监测乳腺癌新辅助化疗的初步经验
前瞻性研究纳入17例拟行新辅助化疗的乳腺癌女性,在化疗前及完成10%、60%、100%化疗时行三维次谐波辅助压力估计(SHAPE)和次谐波成像,比较肿瘤与周围组织的信号差异与最终治疗反应。完成10%化疗时,反应者的肿瘤次谐波信号增幅大于部分反应者或无反应者(SHAPE 3.23 dB±1.41 vs -0.88 dB±1.46,P=.001;次谐波成像 1.32 dB±0.73 vs -0.82 dB±0.88,P=.002),提示SHAPE和次谐波成像有潜力在完成10%化疗时预测新辅助化疗反应,但基于小样本。
要点
- 完成10%化疗时,反应者肿瘤SHAPE信号增幅3.23 dB±1.41,大于部分反应者或无反应者的-0.88 dB±1.46(P=.001)。
- 完成10%化疗时,反应者肿瘤次谐波成像信号增幅1.32 dB±0.73,大于部分反应者或无反应者的-0.82 dB±0.88(P=.002)。
- 3例肿瘤测量 initially 增大的患者,在完成10%化疗后经SHAPE和次谐波成像被正确预测为反应者。
核心结论
- SHAPE和次谐波成像有潜力在完成10%新辅助化疗时帮助预测乳腺癌治疗反应,但基于小样本。
研究设计与样本
- HIPAA合规的前瞻性研究,17例计划接受乳腺癌新辅助治疗的女性(年龄范围45-70岁),在治疗前及完成10%、60%、100%化疗时行超声检查,输注超声造影剂期间采集SHAPE和次谐波成像的射频数据。
诊断标准与关键数值
- 反应者定义为肿瘤体积缩小>90%;共6例反应者,5例部分反应者或无反应者;完成10%化疗时SHAPE肿瘤相对周围区域的信号差异:反应者3.23 dB±1.41 vs 部分反应者或无反应者-0.88 dB±1.46(P=.001);次谐波成像:反应者1.32 dB±0.73 vs 部分反应者或无反应者-0.82 dB±0.88(P=.002)。
局限性
- 研究基于小样本。
- 4例患者退出研究,2例患者因技术问题数据被剔除。
- 8例患者完成整个成像方案,另有3例患者在完成10%化疗的成像检查后因疾病进展退出(这些患者计为非反应者)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To determine whether three-dimensional subharmonic aided pressure estimation (SHAPE) and subharmonic imaging can help predict the response of breast cancer to neoadjuvant chemotherapy. Materials and Methods In this HIPAA-compliant prospective study, 17 women (age range, 45-70 years) scheduled to undergo neoadjuvant therapy for breast cancer underwent ultrasonography (US) immediately before therapy and at completion of 10%, 60%, and 100% of chemotherapy. All patients provided written informed consent. At each examination, radiofrequency data were collected from SHAPE and subharmonic imaging during infusion of a US contrast agent. Maximum-frequency magnitude and mean intensity were calculated for SHAPE and subharmonic imaging. The signal differences in the tumor relative to the surrounding area were compared with the final treatment response by using the Student t test. Results Four patients left the study, and data from two patients were discarded because of technical problems. Eight patients completed the entire imaging protocol, and an additional three patients dropped out after the imaging session at completion of 10% of chemotherapy as a result of disease progression (these patients were counted as nonresponders). Patients' imaging outcomes consisted of six responders (tumor volume reduction >90%) and five partial responders or nonresponders. The results at completion of 10% of therapy showed that the subharmonic signal increased more in the tumor than in the surrounding area for responders than in partial responders or nonresponders (mean ± standard deviation, 3.23 dB ± 1.41 vs -0.88 dB ± 1.46 [P = .001], respectively, for SHAPE and 1.32 dB ± 0.73 vs -0.82 dB ± 0.88 [P = .002], respectively, for subharmonic imaging). Moreover, three patients whose tumor measurements initially increased were correctly predicted to be responders with SHAPE and subharmonic imaging after completion of 10% of therapy. Conclusion SHAPE and subharmonic imaging have the potential to help predict response to neoadjuvant chemotherapy for breast cancer as early as completion of 10% of therapy, albeit on the basis of a small sample size. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Nam K, Eisenbrey JR, Stanczak M, et al. Monitoring Neoadjuvant Chemotherapy for Breast Cancer by Using Three-dimensional Subharmonic Aided Pressure Estimation and Imaging with US Contrast Agents: Preliminary Experience. Radiology. 2017. PMID: 28467142. doi:10.1148/radiol.2017161683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。